Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

An add-on training program involving breathing exercises, cold exposure, and meditation attenuates inflammation and disease activity in axial spondyloarthritis - A proof of concept trial.

Buijze GA, De Jong HMY, Kox M, van de Sande MG, Van Schaardenburg D, Van Vugt RM, Popa CD, Pickkers P, Baeten DLP.

PLoS One. 2019 Dec 2;14(12):e0225749. doi: 10.1371/journal.pone.0225749. eCollection 2019.

2.

Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.

de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.

Arthritis Res Ther. 2019 Sep 14;21(1):208. doi: 10.1186/s13075-019-1998-4.

3.

Dysregulated Fcγ receptor IIa-induced cytokine production in dendritic cells of lupus nephritis patients.

Newling M, Fiechter RH, Sritharan L, Hoepel W, van Burgsteden JA, Hak AE, van Vollenhoven RF, van de Sande MGH, Baeten DLP, den Dunnen J.

Clin Exp Immunol. 2020 Jan;199(1):39-49. doi: 10.1111/cei.13371. Epub 2019 Oct 7.

4.

Treat to target in PsA should focus on clinical measures. Response to: 'DAPSA versus cDAPSA: do we need use CRP?' by Gonçalves et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC.

Ann Rheum Dis. 2019 Jul 22. pii: annrheumdis-2019-215990. doi: 10.1136/annrheumdis-2019-215990. [Epub ahead of print] No abstract available.

PMID:
31331923
5.

Low specificity but high sensitivity of inflammatory back pain criteria in rheumatology settings in Europe: confirmation of findings from a German cohort study.

de Hooge M, van Gaalen FA, Renson T, De Craemer AS, van de Sande MG, Ramonda R, Fagerli KM, Jacobsson LTH, van der Heijde D, Elewaut D, Van den Bosch F.

Ann Rheum Dis. 2019 Nov;78(11):1605-1606. doi: 10.1136/annrheumdis-2019-215742. Epub 2019 Jul 13. No abstract available.

PMID:
31302595
6.

Correction: HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Nov;20(8):690. doi: 10.1038/s41435-019-0076-x.

PMID:
31068685
7.

HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort.

de Winter JJ, Blijdorp IC, de Jong HM, Sauter J, Schmidt AH, van Gaalen FA, van der Heijde D, Poddubnyy D, Yeremenko NG, van de Sande MG, Baeten DL.

Genes Immun. 2019 Nov;20(8):671-677. doi: 10.1038/s41435-019-0061-4. Epub 2019 Feb 26. Erratum in: Genes Immun. 2019 May 9;:.

PMID:
30809016
8.

Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.

van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.

Ann Rheum Dis. 2019 May;78(5):610-616. doi: 10.1136/annrheumdis-2018-214746. Epub 2019 Feb 26.

9.

Peripheral disease contributes significantly to the level of disease activity in axial spondyloarthritis.

de Winter JJ, Paramarta JE, de Jong HM, van de Sande MG, Baeten DL.

RMD Open. 2019 Jan 11;5(1):e000802. doi: 10.1136/rmdopen-2018-000802. eCollection 2019.

10.

Interleukin-17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis.

van Tok MN, van Duivenvoorde LM, Kramer I, Ingold P, Pfister S, Roth L, Blijdorp IC, van de Sande MGH, Taurog JD, Kolbinger F, Baeten DL.

Arthritis Rheumatol. 2019 Apr;71(4):612-625. doi: 10.1002/art.40770. Epub 2019 Feb 18.

PMID:
30390386
11.

First-degree relatives of axial spondyloarthritis patients of the pre-SpA cohort would consider using medication in a preventive setting.

de Winter JJ, de Jong HM, Nieuwkerk PT, van der Horst-Bruinsma IE, Baeten DL, van de Sande MG.

Clin Rheumatol. 2019 Mar;38(3):755-759. doi: 10.1007/s10067-018-4325-6. Epub 2018 Oct 23.

PMID:
30353386
12.

Expansion of Interleukin-22- and Granulocyte-Macrophage Colony-Stimulating Factor-Expressing, but Not Interleukin-17A-Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis.

Blijdorp ICJ, Menegatti S, van Mens LJJ, van de Sande MGH, Chen S, Hreggvidsdottir HS, Noordenbos T, Latuhihin TE, Bernink JH, Spits H, Rogge L, Baeten DLP, Yeremenko NG.

Arthritis Rheumatol. 2019 Mar;71(3):392-402. doi: 10.1002/art.40736. Epub 2019 Jan 15.

13.

The Initiation, but Not the Persistence, of Experimental Spondyloarthritis Is Dependent on Interleukin-23 Signaling.

van Tok MN, Na S, Lao CR, Alvi M, Pots D, van de Sande MGH, Taurog JD, Sedgwick JD, Baeten DL, van Duivenvoorde LM.

Front Immunol. 2018 Jul 9;9:1550. doi: 10.3389/fimmu.2018.01550. eCollection 2018.

14.

Brief Report: Interleukin-17 Blockade With Secukinumab in Peripheral Spondyloarthritis Impacts Synovial Immunopathology Without Compromising Systemic Immune Responses.

van Mens LJJ, van de Sande MGH, Menegatti S, Chen S, Blijdorp ICJ, de Jong HM, Fluri IA, Latuhihin TE, van Kuijk AWR, Rogge L, Yeremenko NG, Baeten DLP.

Arthritis Rheumatol. 2018 Dec;70(12):1994-2002. doi: 10.1002/art.40581. Epub 2018 Oct 17.

15.

Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten DLP, Coates LC.

Ann Rheum Dis. 2019 Jul;78(7):e62. doi: 10.1136/annrheumdis-2018-213618. Epub 2018 May 18. No abstract available.

PMID:
29776975
16.

Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis.

van de Sande MGH, van Vollenhoven RF.

Curr Opin Rheumatol. 2018 Jul;30(4):340-346. doi: 10.1097/BOR.0000000000000516. Review.

PMID:
29697434
17.

Anti-CD74 antibodies have no diagnostic value in early axial spondyloarthritis: data from the spondyloarthritis caught early (SPACE) cohort.

de Winter JJ, van de Sande MG, Baerlecken N, Berg I, Ramonda R, van der Heijde D, van Gaalen FA, Witte T, Baeten DL.

Arthritis Res Ther. 2018 Mar 1;20(1):38. doi: 10.1186/s13075-018-1535-x.

18.

Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.

van Mens LJJ, van de Sande MGH, van Kuijk AWR, Baeten D, Coates LC.

Ann Rheum Dis. 2018 Feb;77(2):251-257. doi: 10.1136/annrheumdis-2017-211998. Epub 2017 Oct 28.

PMID:
29080861
19.

Comment on: Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement: reply.

van Mens LJJ, van de Sande MGH, Baeten DLP.

Rheumatology (Oxford). 2018 Feb 1;57(2):402. doi: 10.1093/rheumatology/kex402. No abstract available.

PMID:
29077921
20.

Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice.

van Mens LJJ, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP.

Arthritis Res Ther. 2017 Oct 10;19(1):226. doi: 10.1186/s13075-017-1424-8.

21.

New treatment paradigms in spondyloarthritis.

van Mens LJJ, van de Sande MGH, Baeten DLP.

Curr Opin Rheumatol. 2018 Jan;30(1):79-86. doi: 10.1097/BOR.0000000000000457. Review.

PMID:
28984648
22.

Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats.

van Tok MN, Satumtira N, Dorris M, Pots D, Slobodin G, van de Sande MG, Taurog JD, Baeten DL, van Duivenvoorde LM.

Front Immunol. 2017 Aug 7;8:920. doi: 10.3389/fimmu.2017.00920. eCollection 2017.

23.

Residual disease activity in psoriatic arthritis: discordance between the rheumatologist's opinion and minimal disease activity measurement.

van Mens LJJ, Turina MC, van de Sande MGH, Nurmohamed MT, van Kuijk AWR, Baeten DLP.

Rheumatology (Oxford). 2018 Feb 1;57(2):283-290. doi: 10.1093/rheumatology/kex183.

PMID:
28541484
24.

Immunopathology of synovitis: from histology to molecular pathways.

van de Sande MG, Baeten DL.

Rheumatology (Oxford). 2016 Apr;55(4):599-606. doi: 10.1093/rheumatology/kev330. Epub 2015 Sep 10. Review.

PMID:
26359330
25.

Expression of Prostaglandin E2 Enzymes in the Synovium of Arthralgia Patients at Risk of Developing Rheumatoid Arthritis and in Early Arthritis Patients.

de Hair MJ, Leclerc P, Newsum EC, Maijer KI, van de Sande MG, Ramwadhdoebe TH, van Schaardenburg D, van Baarsen LG, Korotkova M, Gerlag DM, Tak PP, Jakobsson PJ.

PLoS One. 2015 Jul 30;10(7):e0133669. doi: 10.1371/journal.pone.0133669. eCollection 2015.

26.

Reproducibility of DCE-MRI time-intensity curve-shape analysis in patients with knee arthritis: A comparison with qualitative and pharmacokinetic analyses.

van der Leij C, Lavini C, van de Sande MG, de Hair MJ, Wijffels C, Maas M.

J Magn Reson Imaging. 2015 Dec;42(6):1497-506. doi: 10.1002/jmri.24933. Epub 2015 Apr 29.

PMID:
25929459
27.

Reply: To PMID 24574210.

de Hair MJ, van de Sande MG, Ramwadhdoebe TH, van der Leij C, Maas M, Hansson M, Klareskog L, Landewé R, Serre G, van Schaardenburg D, Gerlag DM, van Baarsen LG, Tak PP.

Arthritis Rheumatol. 2014 Jun;66(6):1683-4. doi: 10.1002/art.38411. No abstract available.

28.

Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis.

de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LG, Tak PP.

Arthritis Rheumatol. 2014 Mar;66(3):513-22. doi: 10.1002/art.38273.

29.

Local synovial engagement of angiogenic TIE-2 is associated with the development of persistent erosive rheumatoid arthritis in patients with early arthritis.

van de Sande MG, de Launay D, de Hair MJ, García S, van de Sande GP, Wijbrandts CA, Gerlag DM, Reedquist KA, Tak PP.

Arthritis Rheum. 2013 Dec;65(12):3073-83. doi: 10.1002/art.38128.

30.

Peripheral joint inflammation in early onset spondyloarthritis is not specifically related to enthesitis.

Paramarta JE, van der Leij C, Gofita I, Yeremenko N, van de Sande MG, de Hair MJ, Tak PP, Maas M, Baeten D.

Ann Rheum Dis. 2014 Apr;73(4):735-40. doi: 10.1136/annrheumdis-2012-203155. Epub 2013 Apr 25.

PMID:
23619158
31.

Smoking and overweight determine the likelihood of developing rheumatoid arthritis.

de Hair MJ, Landewé RB, van de Sande MG, van Schaardenburg D, van Baarsen LG, Gerlag DM, Tak PP.

Ann Rheum Dis. 2013 Oct;72(10):1654-8. doi: 10.1136/annrheumdis-2012-202254. Epub 2012 Oct 27.

32.

Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool.

de Hair MJ, Zijlstra IA, Boumans MJ, van de Sande MG, Maas M, Gerlag DM, Tak PP.

Ann Rheum Dis. 2012 Nov;71(11):1911-2. doi: 10.1136/annrheumdis-2012-201540. Epub 2012 Jun 11. No abstract available.

PMID:
22689316
33.

The features of the synovium in early rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria.

van de Sande MG, de Hair MJ, Schuller Y, van de Sande GP, Wijbrandts CA, Dinant HJ, Gerlag DM, Tak PP.

PLoS One. 2012;7(5):e36668. doi: 10.1371/journal.pone.0036668. Epub 2012 May 4.

34.

Characteristics of synovial inflammation in early arthritis analysed by pixel-by-pixel time-intensity curve shape analysis.

van de Sande MG, van der Leij C, Lavini C, Wijbrandts CA, Maas M, Tak PP.

Rheumatology (Oxford). 2012 Jul;51(7):1240-5. doi: 10.1093/rheumatology/kes011. Epub 2012 Feb 28.

PMID:
22375037
35.

Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease.

Klarenbeek PL, de Hair MJ, Doorenspleet ME, van Schaik BD, Esveldt RE, van de Sande MG, Cantaert T, Gerlag DM, Baeten D, van Kampen AH, Baas F, Tak PP, de Vries N.

Ann Rheum Dis. 2012 Jun;71(6):1088-93. doi: 10.1136/annrheumdis-2011-200612. Epub 2012 Jan 31.

PMID:
22294635
36.

Necrotizing fasciitis in a rheumatoid arthritis patient treated with tocilizumab.

van de Sande MG, van Slobbe-Bijlsma ER.

Rheumatology (Oxford). 2012 Mar;51(3):577-8. doi: 10.1093/rheumatology/ker336. Epub 2011 Nov 16. No abstract available.

PMID:
22096010
37.

Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets.

de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, Wijbrandts CA, van Baarsen LG, Gerlag DM, Tak PP, Reedquist KA.

Ann Rheum Dis. 2012 Mar;71(3):415-23. doi: 10.1136/ard.2010.143529. Epub 2011 Sep 27.

38.

The clinical picture of rheumatoid arthritis according to the 2010 American College of Rheumatology/European League Against Rheumatism criteria: is this still the same disease?

de Hair MJ, Lehmann KA, van de Sande MG, Maijer KI, Gerlag DM, Tak PP.

Arthritis Rheum. 2012 Feb;64(2):389-93. doi: 10.1002/art.33348.

39.

Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase.

van de Sande MG, de Hair MJ, van der Leij C, Klarenbeek PL, Bos WH, Smith MD, Maas M, de Vries N, van Schaardenburg D, Dijkmans BA, Gerlag DM, Tak PP.

Ann Rheum Dis. 2011 May;70(5):772-7. doi: 10.1136/ard.2010.139527. Epub 2010 Dec 21.

PMID:
21177292
40.

Presence of lymphocyte aggregates in the synovium of patients with early arthritis in relationship to diagnosis and outcome: is it a constant feature over time?

van de Sande MG, Thurlings RM, Boumans MJ, Wijbrandts CA, Modesti MG, Gerlag DM, Tak PP.

Ann Rheum Dis. 2011 Apr;70(4):700-3. doi: 10.1136/ard.2010.139287. Epub 2010 Dec 20.

PMID:
21173012
41.

Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials.

van de Sande MG, Gerlag DM, Lodde BM, van Baarsen LG, Alivernini S, Codullo V, Felea I, Vieira-Sousa E, Fearon U, Reece R, Montecucco C, Veale DJ, Pitzalis C, Emery P, Klareskog L, McInnes IB, Tak PP.

Ann Rheum Dis. 2011 Mar;70(3):423-7. doi: 10.1136/ard.2010.139550. Epub 2010 Nov 24.

PMID:
21109518
42.

Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.

Cantaert T, van Baarsen LG, Wijbrandts CA, Thurlings RM, van de Sande MG, Bos C, van der Pouw Kraan TC, Verweij CL, Tak PP, Baeten DL.

Rheumatology (Oxford). 2010 Jan;49(1):156-66. doi: 10.1093/rheumatology/kep345. Epub 2009 Nov 23. Erratum in: Rheumatology (Oxford). 2014 Apr;53(4):770. van der Pouw, Tineke Kraan [corrected to van der Pouw Kraan, Tineke C T M].

PMID:
19933783
43.

Rheumatoid synovial inflammation: pixel-by-pixel dynamic contrast-enhanced MR imaging time-intensity curve shape analysis--a feasibility study.

van der Leij C, van de Sande MG, Lavini C, Tak PP, Maas M.

Radiology. 2009 Oct;253(1):234-40. doi: 10.1148/radiol.2531081722. Epub 2009 Jul 31.

PMID:
19703863
44.

The Ras guanine nucleotide exchange factor RasGRF1 promotes matrix metalloproteinase-3 production in rheumatoid arthritis synovial tissue.

Abreu JR, de Launay D, Sanders ME, Grabiec AM, van de Sande MG, Tak PP, Reedquist KA.

Arthritis Res Ther. 2009;11(4):R121. doi: 10.1186/ar2785. Epub 2009 Aug 13.

45.

Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers.

Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG, Veale D, Vos K, Tak PP.

J Rheumatol. 2009 Aug;36(8):1800-2. doi: 10.3899/jrheum.090348.

PMID:
19671815
46.

Pixel-by-pixel analysis of DCE MRI curve patterns and an illustration of its application to the imaging of the musculoskeletal system.

Lavini C, de Jonge MC, van de Sande MG, Tak PP, Nederveen AJ, Maas M.

Magn Reson Imaging. 2007 Jun;25(5):604-12. Epub 2006 Dec 8.

PMID:
17540271
47.

The role of chemokines in rheumatoid arthritis and osteoarthritis.

Vergunst CE, van de Sande MG, Lebre MC, Tak PP.

Scand J Rheumatol. 2005 Nov-Dec;34(6):415-25. Review.

PMID:
16393761

Supplemental Content

Loading ...
Support Center